A new fixed-dose tablet (PrandiMet – Novo Nordisk) combining metformin (Glucophage, and others) and repaglinide (Prandin) has been approved by the FDA for treatment of type 2 diabetes in patients already taking both metformin and repaglinide, or for patients not adequately controlled on either drug alone.

FIXED-DOSE COMBINATIONS — When patients with diabetes require more than one drug to achieve glycemic goals, most clinicians prescribe a second drug with a different mechanism of action.1 Metformin, which is often the first drug used, is already available in fixed-dose combinations with the sulfonylureas glipizide (Metaglip, and others) and glyburide (Glucovance, and others), with the thiazolidinediones pioglitazone (Actoplus Met) and rosiglitazone (Avandamet), and with the DPP-4 inhibitor sitagliptin ... more      

Would you like to read the rest of this article?  Gain access below.